DFDA

COMT Inhibitors (e.g., Entacapone)

Treatment for Parkinson S Disease

Typical Dosage: Entacapone 200 mg with each levodopa dose (max 8 doses daily)

Effectiveness
65%
Safety Score
65%
Clinical Trials
50
Participants
10K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
Entacapone 200 mg with each levodopa dose (max 8 doses daily)
Time to Effect
Immediate
Treatment Duration
Lifetime (as adjunct to levodopa)
Evidence Quality
HIGH
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$1,000
Monitoring:$1,000
Side Effect Mgmt:$200
Total Annual:$2,200
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
ICER
$55,000/QALY
QALYs Gained
0.4
Outcome-Based Costs
Cost per Responder
$1,846.15
COMT Inhibitors (e.g., Entacapone) Outcomes

for Parkinson S Disease

Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+65%
Common Side Effects
Diarrhea
+15%
Nausea
+12%
Worsened dyskinesia
+15%
Orange-brown urine discoloration
+100%

Sources:

nih.gov
nih.gov
mdsabstracts.org

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov